San Francisco, CA, United States of America

Isaac J Rondon

USPTO Granted Patents = 14 


 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 18(Granted Patents)


Location History:

  • Boston, MA (US) (2004 - 2005)
  • Berkeley, CA (US) (2013)
  • San Francisco, CA (US) (2008 - 2022)

Company Filing History:


Years Active: 2004-2025

Loading Chart...
Loading Chart...
Loading Chart...
14 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Isaac J Rondon

Introduction

Isaac J Rondon is a prominent inventor based in San Francisco, CA. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. With a total of 14 patents to his name, Rondon's work has the potential to impact cancer treatment and other medical applications.

Latest Patents

Among his latest patents, Rondon has developed materials and methods for CUB domain-containing protein 1 (CDCP1)-targeted therapy. This innovative approach aims to provide effective treatment options for cancer patients. Additionally, he has invented a method of treating cancer using anti-AV8 antibodies, which specifically bind to αvβ8 integrin. This invention includes various uses and associated methods for utilizing these antibodies in therapeutic settings.

Career Highlights

Throughout his career, Rondon has worked with notable organizations such as Pfizer Corporation and the University of California. His experience in these esteemed institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Rondon has collaborated with talented individuals, including Lauren K Ely and Natasha K Crellin. These partnerships have further enhanced his research and development efforts in the biotechnology sector.

Conclusion

Isaac J Rondon's innovative work in the field of biotechnology, particularly in antibody development, showcases his dedication to advancing medical science. His contributions have the potential to lead to significant improvements in cancer treatment and patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…